Skip To Content

Study ID: NantBioScience CMS-005 Breast Cancer

Title:

Phase I Study of Ad5 [E1-, E2b-]-HER2/neu Vaccine (ETBX-021) in Subjects with Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer

Location:
Sioux Falls Region
Principal Investigator:
Amy Sanford, MD
Disease:
Breast - Invasive
Stage:
Phase I
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.